Introduction: Expanding the Role of Medical Affairs
Medical Affairs occupies a unique position as one of the few functions trusted to engage credibly and compliantly on scientific evidence across the healthcare ecosystem.
While its influence on healthcare professionals (HCPs) is well-documented, its role increasingly extends to patients, caregivers, and patient advocacy organizations, all of whom shape how therapies are understood, accessed, and used.
Bain reports that a significant portion of HCPs modify aspects of their clinical practice after engaging with a medical science liaison, highlighting the real-world effect of structured scientific exchange (bain.com).
Medical Affairs ROI can be shown when scientific engagement is tied to defined outcomes such as HCP behavior change, patient adherence, and evidence adoption. The challenge is linking engagement activity to these outcomes in a way that informs decisions.
Medical Affairs is still often viewed as a cost center rather than a strategic contributor. The gap is not activity, but measurement and alignment to outcomes across stakeholders and functions.
Key takeaways
- Medical Affairs ROI is measurable when engagement is connected to outcomes, not activity volume.
- Scientific exchange beyond HCPs influences adoption, adherence, and lifecycle performance.
- Congresses and hybrid events remain high-value environments when objectives, insights, and follow‑up are aligned.
1. How to Define Medical Affairs Value Across Stakeholders
Any credible approach to ROI begins with shared definitions of value and impact.
The Medical Affairs Professional Society (MAPS) emphasizes the importance of consistent language and metrics across the Medical Affairs lifecycle (medicalaffairs.org). Without shared definitions, measurement remains fragmented and difficult to act on.
Importantly, value should not be defined solely by HCP engagement. Scientific education for patients, evidence-based dialogue with caregivers, and disease awareness efforts with advocacy organizations all influence how therapies are adopted and used in practice.
Research from the ROI Institute shows that structured ROI frameworks support better alignment, more efficient resource allocation, and clearer visibility into patient-centric outcomes (roiinstituteacademy.com).
In practice, value must be defined in terms of outcomes, not activity.
This requires mapping each engagement type to a defined outcome, such as clinical decision influence, patient adherence, or insight generation, rather than treating engagement itself as the end point.
2. Enable Credible Scientific Engagement Beyond HCPs
Medical Affairs exists to bridge scientific evidence and real-world understanding.
When teams deliver timely, relevant, and non-promotional information, they can become trusted partners not only to clinicians but also to patients and advocacy communities seeking clarity around disease state, evidence, and evolving standards of care.
Patients and caregivers influence adherence and persistence, while advocacy organizations shape education and access conversations. Medical Affairs is uniquely positioned to support these stakeholders through scientifically grounded, compliant engagement.
This expands the role of Medical Affairs from information delivery to influencing how therapies are understood and sustained in real-world use, making these interactions relevant to both medical and commercial performance.
3. Use Data and AI to Focus Effort Where It Matters Most
As engagement expands across audiences, structured insight management becomes essential.
Capturing and interpreting insights from HCPs, patients, caregivers, and advocacy groups allows Medical Affairs teams to identify unmet needs and prioritize high-impact activities.
Analytics and AI-enabled insight management can help triage information, identify patterns, and align engagement strategies with defined objectives (tikamobile.com). The value of these tools is not volume of data, but the ability to connect insight to action and measurable outcomes
Without this linkage, insight collection remains descriptive rather than decision-driving, limiting its usefulness across clinical development, launch planning, and post-launch optimization..
4. How Omnichannel Engagement Extends Medical Affairs Impact
Scientific engagement now takes place across multiple channels and formats.
MAPS notes that omnichannel approaches enable consistent, personalized scientific exchange across digital and live environments (medicalaffairs.org). These approaches apply equally to patient and advocacy engagement, where consistency of message and continuity of insight are critical.
Diversified influencer networks, including micro-KOLs, play a growing role in disseminating scientific information and insights within specialized clinical and patient communities (tikamobile.com). Omnichannel execution increases reach, but its value depends on consistency of message and follow-through on insights generated.
The objective is not channel expansion. It is sustained, consistent scientific exchange that reinforces key evidence and insights across touchpoints.
5. How Can Medical Affairs Impact Be Measured Beyond Activity Metrics?
Measurement is most useful when it reflects real engagement environments.
Scientific congresses, patient forums, and hybrid events remain valuable when approached with clear objectives and structured follow-up. Advance planning and targeted meetings improve engagement quality and efficiency, particularly in high-investment environments such as congresses (thelightstreamgroup.com).
At the same time, digital and hybrid models expand reach. A significant portion of audiences engage exclusively through online formats, reinforcing the need to measure impact across both in‑person and virtual settings (pharma.pri-med.com).
MAPS KPI scorecard provides a practical framework for tracking Medical Affairs performance across scientific exchange, educational reach, and insight generation (medicalaffairs.org).
When aligned with organizational goals, these metrics help position Medical Affairs as a strategic partner rather than a siloed function.
Conclusion: Making Scientific Impact Visible
Medical Affairs is no longer a behind-the-scenes support function.
It is a core link between scientific evidence and the stakeholders who influence how therapies are adopted, understood, and sustained.
By defining value across stakeholders, aligning engagement to insight, and applying structured measurement frameworks, organizations can make Medical Affairs’ contribution visible and measurable. This allows Medical Affairs to be evaluated against other investments based on its contribution to clinical adoption, patient outcomes, and lifecycle performance.
Reverba Global works with biopharma teams to strengthen scientific engagement across the healthcare ecosystem, helping Medical Affairs translate insight into measurable, real-world impact. Start a conversation with our team →
